MANE Veradermics, Incorporated

Bloomberg reported on August 29 that hair-loss drug stocks are surging as Wall Street bets on a new pharmaceutical goldmine following the GLP-1 weight-loss boom. Shares of Veradermics, Incorporated (NYSE:MANE) have climbed nearly 500% since its February 2026 initial public offering, while Absci Corporation (NASDAQ:ABSI)’s stock has more than doubled so far in 2026. Switzerland’s […]

Veradermics has delivered a very strong year-to-date share price gain, yet the valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. The stock is up 160.8% year to date, which means anyone buying now is stepping in after a very sharp re-rating. Future valuation for Veradermics can hinge on how effectively the company converts its growth opportunities into durable cash flow, while any stumble on execution or profitability could...

Veradermics (MANE) drew investor attention after recent trading data highlighted a year to date return above 160%, a market value of about US$4.1b and a last close of US$98.46. Over the shorter term, Veradermics has given back some ground, with the 7 day share price return down 4.22% and the 30 day share price return down 3.37%. However, the year to date share price return of 160.82% suggests momentum has still been strong overall. Compare the surge in Veradermics with a curated group of...

Hair loss biotechs Veradermics, Absci, and Cosmo are drawing investor bets on a market untouched since the 1990s.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

Veradermics Incorporated on Wednesday released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss. The company said the treatment produced consistent hair growth, demonstrated an early onset of activity, and...

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the

Veradermics (NYSE:MANE) said results from the female arms of Study 207, a phase II open-label trial of VDPHL01 for mild to moderate pattern hair loss, showed what company executives described as a strong proof-of-concept signal for the oral treatment. Chief Executive Officer Dr. Reid Waldman said t